Objective To investigate the association of high-density lipoprotein cholesterol (HDL-C) with the prognosis of patients with alcohol-related hepatocellular carcinoma (HCC) after radical treatment.Methods A retrospective analysis was performed for the clinical data of 43 patients with alcohol-related HCC who were admitted to The Fifth Medical Center of Chinese PLA General Hospital and underwent radical treatment from January 2008 to July 2015, and according to HDL-C level, the patients were divided into normal group with 26 patients and abnormal group with 17 patients. The two groups were compared in terms of basic information, laboratory markers, imaging indices, Barcelona Clinic Liver Cancer tumor stage, and Child-Pugh class of liver function. The t-test test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between two groups. The Kaplan-Meier method was used to plot survival curves and the log-rank test was used for comparison between groups. Univariate and multivariate Cox proportional hazards models were used to analyze independent risk factors for prognosis.Results There was a significant difference in prealbumin between the two groups (162.38±60.86 mg/L vs 120.06±64.08 mg/L, t=2.184, P=0.035). Number of tumors (hazard ratio [HR]=2.839, 95%confidence interval [CI]: 1.120~7.200, P=0.028), tumor size (HR=2.634, 95%CI: 1.062~6.529, P=0.037), and HDL-C level (HR=2.400, 95%CI: 1.040~5.537, P=0.040) were independent risk factors for the overall survival of patients with alcohol-related HCC. There were significant differences in 1-, 3-, and 5-year cumulative survival rates between the normal group and the abnormal group (88.5%/72.4%/55.7% vs 70.6%/43.7%/17.5%, χ2=5.881, P=0.015).Conclusion The reduction in HDL-C level might indicate poor prognosis of patients with alcohol-related HCC.
流式细胞术检测慢病毒感染5天后的BEL-7404细胞周期,沉默组的G1期细胞比例显著高于对照组(49.9%±0.8% vs 44.0%±0.9%,t=8.96,P<0.001),G2/M期细胞比例显著低于对照组(15.9%±0.2% vs 17.9%±0.7%,t=9.13,P<0.001),S期细胞比例显著低于对照组(34.2%±0.6% vs 38.1%±0.5%,t=6.91,P<0.001)(图6)。
图
6
不同处理组BEL-7404细胞周期情况
Figure
6.
Cell cycle of BEL-7404 cells in different treatment groups
EME1对于哺乳动物细胞中 DNA 代谢的各个方面都很重要,Guo等[10]研究发现EME1与胃癌细胞AGS和MGC-803的增殖及侵袭能力密切相关,沉默EME1基因表达可通过抑制蛋白激酶B活化,降低糖原合酶激酶-3β、细胞周期蛋白D1,从而抑制癌细胞增殖和侵袭,促进细胞凋亡。基于中国广西人群的研究[11]发现EME1的Glu69Asp错义多态性与肝癌风险增加显著相关。EME1的另一外显子Ile350Thr变异会提高乳腺癌的易感性[12]。
BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492
KITAHARA CM, BERRINGTON de GONZÁLEZ A, FREEDMAN ND, et al. Total cholesterol and cancer risk in a large prospective study in Korea[J]. J Clin Oncol, 2011, 29(12): 1592-1598. DOI: 10.1200/JCO.2010.31.5200
[4]
GAO XH, ZHANG SS, CHEN H, et al. Systemic hepatic-damage index for predicting the prognosis of hepatocellular carcinoma after curative resection[J]. Front Physiol, 2017, 8: 480. DOI: 10.3389/fphys.2017.00480
[5]
National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association. Diagnostic criteria of alcoholic fatty liver disease[J]. World J Infect, 2001, 1(5): 482. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZHGZ200302003.htm
Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.02.007
LI D, ZHAO H, ZHOU H, et al. The clinical characteristics and the image presentation of CT and MRI of hepatocellular carcinoma based on alcoholic liver cirrhosis[J]. J Med Sci Cent South China, 2015, 43(6): 632-636. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-HYYY201506009.htm
COSTENTIN CE, MOURAD A, LAHMEK P, et al. Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: Results of a prospective, nationwide study[J]. Cancer, 2018, 124(9): 1964-1972. DOI: 10.1002/cncr.31215
[9]
GEORGILA K, VYRLA D, DRAKOS E. Apolipoprotein A-Ⅰ (ApoA-Ⅰ), immunity, inflammation and cancer[J]. Cancers (Basel), 2019, 11(8): 1097. DOI: 10.3390/cancers11081097
[10]
YE J, LUO Q Y, WANG X P, et al. Serum apolipoprotein A-Ⅰ combined with C-reactive protein serves as a novel prognostic stratification system for colorectal cancer[J]. Cancer Manag Res, 2019, 11: 9265-9276. DOI: 10.2147/CMAR.S215599
[11]
TATEMATSU S, FRANCIS SA, NATARAJAN P, et al. Endothelial lipase is a critical determinant of high-density lipoprotein-stimulated sphingosine 1-phosphate-dependent signaling in vascular endothelium[J]. Arterioscler Thromb Vasc Biol, 2013, 33(8): 1788-1794. DOI: 10.1161/ATVBAHA.113.301300
TRIEB M, RAINER F, STADLBAUER V, et al. HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure[J]. J Hepatol, 2020, 73(1): 113-120. DOI: 10.1016/j.jhep.2020.01.026
[14]
OOI K, SHIRAKI K, SAKURAI Y, et al. Clinical significance of abnormal lipoprotein patterns in liver diseases[J]. Int J Mol Med, 2005, 15(4): 655-660. http://europepmc.org/abstract/MED/15754028
[15]
MOTTA M, GIUGNO I, RUELLO P, et al. Lipoprotein (a) behaviour in patients with hepatocellular carcinoma[J]. Minerva Med, 2001, 92(5): 301-305. http://www.ncbi.nlm.nih.gov/pubmed/11675573
[16]
FUJII S, KOGA S, SHONO T, et al. Serum apoprotein A-Ⅰ and A-Ⅱ levels in liver diseases and cholestasis[J]. Clin Chim Acta, 1981, 115(3): 321-331. DOI: 10.1016/0009-8981(81)90245-X
[17]
HUANG WC, CHEN X, YU JL, et al. Value of serum high-density lipoprotein cholesterol levels in evaluating liver function[J]. China Med Pharm, 2014, 4(13): 118-119, 142. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-GYKX201413044.htm
BEEGHLY-FADIEL A, KHANKARI NK, DELAHANTY RJ, et al. A Mendelian randomization analysis of circulating lipid traits and breast cancer risk[J]. Int J Epidemiol, 2020, 49(4): 1117-1131. DOI: 10.1093/ije/dyz242
SCHAIRER C, LAURENT CA, MOY LM, et al. Obesity and related conditions and risk of inflammatory breast cancer: A nested case-control study[J]. Breast Cancer Res Treat, 2020, 183(2): 467-478. DOI: 10.1007/s10549-020-05785-1
[21]
QU F, CHEN R, PENG Y, et al. Assessment of the predictive role of serum lipid profiles in breast cancer patients receiving neoadjuvant chemotherapy[J]. J Breast Cancer, 2020, 23(3): 246-258. DOI: 10.4048/jbc.2020.23.e32
YU JF. Analysis of abnormal levels of blood lipid and homocysteine in patients with different types of malignant tumors[D]. Nanning: Guangxi Medical University), 2017. (in Chinese)
ZOU Y, WU L, YANG Y, et al. Serum lipid levels correlate to the progression of gastric cancer with neuroendocrine immunophenotypes: A multicenter retrospective study[J]. Transl Oncol, 2021, 14(1): 100925. DOI: 10.1016/j.tranon.2020.100925
[25]
BRANTLEY KD, RIIS AH, ERICHSEN R, et al. The association of serum lipid levels with colorectal cancer recurrence[J]. Cancer Epidemiol, 2020, 66: 101725. DOI: 10.1016/j.canep.2020.101725
[26]
YUAN B, FU J, YU WL, et al. Prognostic value of serum high-density lipoprotein cholesterol in patients with gallbladder cancer[J]. Rev Esp Enferm Dig, 2019, 111(11): 839-845. http://www.ncbi.nlm.nih.gov/pubmed/31595756
[27]
SAITO N, SAIRENCHI T, IRIE F, et al. Low serum LDL cholesterol levels are associated with elevated mortality from liver cancer in Japan: The Ibaraki Prefectural health study[J]. Tohoku J Exp Med, 2013, 229(3): 203-211. DOI: 10.1620/tjem.229.203
[28]
ZHAN CL. Serum makers of lipid metabolism as a new prognostic factor in cancer: A meta-analysis[D]. Suzhou: Soochow University, 2019. (in Chinese)
JIANG SS, WENG DS, JIANG L, et al. The clinical significance of preoperative serum cholesterol and high-density lipoprotein-cholesterol levels in hepatocellular carcinoma[J]. J Cancer, 2016, 7(6): 626-632. DOI: 10.7150/jca.13837
[30]
CARR BI, GIANNELLI G, GUERRA V, et al. Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients[J]. Int J Biol Markers, 2018, 33(4): 423-431. DOI: 10.1177/1724600818776838
[31]
ZHONG GC, HUANG SQ, PENG Y, et al. HDL-C is associated with mortality from all causes, cardiovascular disease and cancer in a J-shaped dose-response fashion: A pooled analysis of 37 prospective cohort studies[J]. Eur J Prev Cardiol, 2020, 27(11): 1187-1203. DOI: 10.1177/2047487320914756
PU Zaichun, JIA Ping, LIU Juan, et al. Risk prediction models for pancreatic fistula after pancreaticoduodenectomy: A systematic review and a Meta-analysis[J]. J Clin Hepatol, 2024, 40(11): 2266-2276. DOI: 10.12449/JCH241121.
PU Zaichun, JIA Ping, LIU Juan, et al. Risk prediction models for pancreatic fistula after pancreaticoduodenectomy: A systematic review and a Meta-analysis[J]. J Clin Hepatol, 2024, 40(11): 2266-2276. DOI: 10.12449/JCH241121.